Semaglutide News and Research

Latest Semaglutide News and Research

Who gets obesity drugs covered by insurance? In North Carolina, it helps if you’re on Medicaid

Who gets obesity drugs covered by insurance? In North Carolina, it helps if you’re on Medicaid

Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication

Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication

Expert explores the expanding applications of GLP1 therapies

Expert explores the expanding applications of GLP1 therapies

Can fasting improve diabetes outcomes? Ramadan offers insights

Can fasting improve diabetes outcomes? Ramadan offers insights

GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events

GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

How neural and hormonal gut-brain communication shapes metabolism and health

How neural and hormonal gut-brain communication shapes metabolism and health

New oral peptide therapy offers hope for chronic abdominal pain

New oral peptide therapy offers hope for chronic abdominal pain

Anti-obesity drugs increase food waste in some users

Anti-obesity drugs increase food waste in some users

Ingestible capsule releases a burst of drugs directly into the walls of the GI tract

Ingestible capsule releases a burst of drugs directly into the walls of the GI tract

Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure

Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure

Squid-inspired technology could replace needles for medications and vaccines

Squid-inspired technology could replace needles for medications and vaccines

More than half of all US adults are eligible for semaglutide therapy

More than half of all US adults are eligible for semaglutide therapy

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder

GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder

Sapio Sciences Collaborates with Waters Corporation to Improve Efficiency of Laboratory Operations

Sapio Sciences Collaborates with Waters Corporation to Improve Efficiency of Laboratory Operations

Intravenous infusion of exenatide fails to reduce risks of complications in heart surgery patients

Intravenous infusion of exenatide fails to reduce risks of complications in heart surgery patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.